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Background: Therapeutic approaches to addressing insufficient lactation are available but remain poorly understood. Current
trends in maternal health, such as increasing rates of obesity, delayed age at childbearing, and high rates of cesarean section,
may be associated with physiological challenges for lactation that cannot be managed by counseling alone. Women who have
not had success with counseling alone, including adoptive mothers seeking to induce lactation, may use galactagogues
(pharmaceutical and herbal compounds used to increase lactation). We present a review of selected studies of galactagogues
and data indicating popular demand for such products.
Methods: A systematic search was conducted for published studies on the use of galactagogues for breast-feeding. The
following databases were searched: MEDLINE (PubMed), EBSCO (Academic Search Complete), and EMBASE. The search was
conducted between July 15, 2015, and August 18, 2015; only English language articles were included, and we imposed no
restrictions on publication date. Two authors independently reviewed the studies and extracted data.
Results: Blinded, placebo-controlled clinical trials of 2 pharmaceutical galactagogues (domperidone and metoclopramide) and
5 popular herbal galactagogues (shatavari, fenugreek, silymarin, garlic, and malunggay) were identified. All of the studies
identified for domperidone showed a significant difference in milk production between the treatment and placebo groups. Of
the 6 trials of metoclopramide, only 1 study showed a significant difference in milk production compared to placebo. Results of
the clinical trials on herbal galactagogues were mixed. Our review of the evidence for the efficacy of popular pharmaceutical
and herbal galactagogues revealed a dearth of high-quality clinical trials and mixed results.
Conclusion: Health providers face the challenge of prescribing or recommending galactagogues without the benefit of robust
evidence. Given the suboptimal rates of exclusive breast-feeding worldwide and the availability and demand for medical and
herbal lactation therapies, controlled trials and analyses investigating these medicines are urgently warranted.
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INTRODUCTION
Breast-feeding newborns and infants provides optimal
nutrition along with immune support and a host of lifelong
health benefits to mother and child.1-3 Yet significant
barriers to breast-feeding persist, and women, particularly
those living in low-income settings, experience social,
psychological, and physiological difficulties that impact
breast-feeding.4,5 In the United States, for example, less
than half of infants receive any breast milk at 6 months
(49.4%), and approximately one-quarter are breast-fed at 1
year (26.7%).5
Professional lactation support should be the cornerstone
of health-service support for postpartum mothers to achieve
breast-feeding practices widely recognized as optimum for
child health and development, including prompt initiation
and exclusive breast-feeding during the first 6 months of
life.3,6,7 Improving access to support and counseling is
vitally important to improving breast-feeding rates. As of
2013, there were only 3.5 international board-certified
lactation consultants and 3.8 certified lactation counselors
per 1,000 live births in the United States.5 Counseling may
not fully address physiological barriers to breast-feeding,
such as primary lactation insufficiency.8,9
Delayed childbearing, high rates of cesarean section,
stressful labor lasting >1 hour, and obesity can create
physiological barriers to the establishment of lactation.3,10,11
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For example, delayed onset of lactogenesis II, defined as
the increase in lactation observed within 72 hours of
delivery, was reported to affect 22%-31% of women
according to studies that took place in California and
Conneticut, respectively.10,11 Risk factors for delayed onset
of lactogenesis II include primiparity, high body mass index,
cesarean section, and stress during labor or prolonged
labor.10,11 Other causes of low milk production may be
generally related to mammary hypoplasia12,13 and use of
analgesics during labor, as well as a family history of alcohol
dependence and obesity, both of which can inhibit the
prolactin response required for milk production immediately
postpartum.14-17 When the onset of milk production is
delayed, breast-feeding is more likely to be halted early, and
newborns are at greater risk of excess neonatal weight
loss,17-19 prompting supplementation with infant formula.
Women with insufficient milk production who do not
respond to lactation counseling, as well as adoptive parents
seeking to induce lactation, may pursue therapy with herbal
and pharmaceutical galactagogues. Available information
suggests that demand for pharmaceutical20,21 and herbal
galactagogues22 is increasing, but guidance on their use is
not widely available. The Academy of Breastfeeding
Medicine currently cites insufficient evidence to recommend
any specific pharmacologic or herbal galactagogues.23 The
purpose of our review is to describe the current evidence on
herbal and pharmaceutical galactagogues in light of the
apparent demand for such products.
METHODS
Between July 15, 2015, and August 18, 2015, we
searched the following databases for published studies of
galactagogues used for breast-feeding and lactation:
MEDLINE (PubMed), EBSCO (Academic Search Complete),
and EMBASE. We did not restrict publication dates for
inclusion. The search strategy consisted of the following
terms solo and in combination: galactagogue, galacto-
gogue, lactagogue, lactogogue, herbal, pharmaceutical,
domperidone, metoclopramide, and lactation. Studies of
herbal galactagogues were identified by searching the Latin
or English name and lactation. The search terms for herbal
galactagogues included milk thistle, Silybum marianum,
fenugreek, Trigonella foenum-graecum, malunggay, Morin-
ga oleifera, garlic, Allium sativum, shatavari, and Asparagus
racemosus. Other popular galactagogues were searched:
blessed thistle, Cnicus benedictus, goat’s rue, Galega
officinalis, fennel, and Foeniculum vulgare. The reference
lists of peer-reviewed publications were also searched by
hand.
Following review and consultation with clinician experts,
we included studies of the pharmaceutical galactagogues
most commonly prescribed (off-label in the United States)
for the specific purpose of augmenting lactation: domper-
idone and metoclopramide. These drugs are also the most
commonly studied in relation to lactation, although other
pharmaceuticals, such as some antipsychotic medica-
tions,24 are also known to affect prolactin production and
potentially to induce or augment lactation. Only articles in
English were reviewed. Studies included were restricted to
blinded, placebo-controlled, randomized trials on human
subjects. Studies were only included if estimated milk
production, infant weight gain, or time to relactation was
an outcome of interest, as these were considered the most
useful for clinical guidance and research strategy.
To develop inclusion criteria for herbal galactagogues, we
consulted experts (lactation counselors) on the most
commonly recommended or used products that are
generally commercially available from the recorded sources
of data described below. Herbal products that were ranked
among the top 40 best-selling herbal dietary supplements
by the American Botanical Council25 and were most
commonly used for inducing lactation in population-based
surveys26,27 were included. Inclusion criteria for review of
studies describing herbal galactagogues were blinded,
placebo-controlled trials, with treatment and control groups
comparable at baseline, either through randomization or
assignment, using only human subjects. Studies were only
included if estimated milk production, infant weight gain,
serum prolactin levels, or time to relactation was an
outcome of interest, as these were considered the most
useful for clinical guidance and research strategy.
We conducted a Google Trends analysis to ascertain the
apparent consumer demand for products to increase breast
milk production among users of the Google search engine.
Google Trends is a freely available, publicly accessible
application of Google Inc. (available at https://www.google.
com/trends) that provides data based on Google searches
to show how often a particular search term is entered
relative to the total search volume across various regions of
the world and in various languages. Google Trends only
analyzes data for popular terms, so search terms with low
volume appear as 0, and it eliminates repeated searches
from the same internet protocol address that are performed
in a short period of time. Google Trends adjusts search data
to facilitate comparisons between terms. Without this
feature, geographic regions with the most search volume
would always be ranked highest. Each data point is divided
by the total searches of the geography and time range it
represents to compare the relative popularity. The resulting
numbers are presented in a scale range of 0-100. We
conducted our analysis on August 18, 2015, using the
search term increase breast milk. Other terms analyzed
were galactagogue and increase lactation, but we excluded
these results because of insufficient search volume and
clarity of trend results.
RESULTS
A total of 731 articles (n¼584 on pharmaceutical galacta-
gogues and n¼147 on herbal galactagogues) were identi-
fied in the initial search, outlined in Figure 1. A total of 466
articles were excluded (n¼350 pharmaceutical and n¼116
herbal) because of use of nonhuman subjects (n¼148 and
n¼100, respectively) and duplication (n¼202 and n¼16,
respectively). The titles and abstracts of 265 articles (n¼234
and n¼31, respectively) were prescreened. Reviews, case
studies, and other nonexperimental studies were then
excluded (n¼176 and n¼14, respectively), and the full text
of the remaining 75 studies was retrieved for review. A total
of 18 studies met the inclusion criteria (n¼10 and n¼8,
respectively).
Pharmaceutical Galactagogues
Domperidone. Table 1 summarizes the 4 studies of
domperidone that we identified (Campbell-Yeo et al
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published their protocol separately).28-32 Several differences
were noted in terms of method of breast milk collection,
criteria for participation, counseling/support provided to
mothers, and duration of treatment. Two studies28-30
analyzed the volume of breast milk expressed via a
mechanical pump during a period of 24 hours, while in
another study,31 mothers collected milk via mechanical
pump from each breast for a period of 15 minutes twice
daily, 2 hours after they breast-fed their infant. Another
study32 estimated milk volume by test-weighing infants
before and after a feeding. Two of the studies31,32 included
participants who delivered at term: the former included
infants delivered via cesarean section whose mothers
showed no evidence of insufficient lactation, and the latter
included infants delivered normally whose mothers had
experienced complete or partial lactation failure. Two
studies included participants who delivered prematurely
and were experiencing insufficient lactation.28-30 In the same
2 studies, counseling on breast-feeding practices was
reported to have been provided to all participants regardless
of assignment before participants entered the study,28-30 and
participants of another study received encouragement to
breast-feed within 24 hours of delivery.31 One study began
treatment on the second day postpartum.32 A high attrition
rate among participants in the treatment group of 1 study was
noted.28 All studies sufficiently described the randomization
process except for Petraglia et al, in which participants were
randomly selected, but the method of allocation into study
arms was not well described.32 The total number of
participants in all studies analyzed was 131.
Despite the differences in methodology, the results of all
included studies indicate significantly more milk output in
mothers treated with 10 mg of domperidone 3 times per
day28-30,32 or 4 times per day31 for 4-14 days compared to
those given a placebo. Figure 2 shows mean milk
production by day of treatment for participants given
domperidone vs placebo. Although the collection protocols
were different, and thus the results are not directly
comparable, an overall trend of higher milk production
among participants treated with domperidone vs placebo is
apparent, and the mean volume of milk produced appears
to continue to increase with the number of days of
treatment. The difference in mean milk volume between
treatment vs placebo groups was statistically significant
within each study at endpoint. A mild side effect (dry mouth)
was reported by participants in 1 study.31
Metoclopramide. Table 2 summarizes the 6 randomized,
double-blind, placebo-controlled trials of metoclopramide
we identified, each using 10 mg 3 times daily for a period of
7-15 days.33-38 Study methodology varied and recruitment
criteria were not uniform. Participants in each study varied:
studies included mothers of healthy infants not experiencing
insufficient lactation,33 mothers described as not experienc-
ing any lactation failure,34,35 mothers of hospitalized infants
experiencing partial or complete lactation failure,36 mothers
of infants who were failing to gain weight (used as a proxy
for lactation failure),37 and mothers who had elective or
emergency cesarean section.38 Outcomes of interest also
varied: 2 studies measured volume of milk produced in
mL,34,35 1 estimated milk production using infant weight
gain by the difference in weight before and after feeding,33
and 2 measured mean infant weight gain in grams.36,37 In
addition to mean infant weight gain, 1 study also evaluated
time to relactation,36 and 1 study only assessed the ability to
successfully establish breast-feeding.38 Lactation counsel-
ing was reportedly provided to all mothers in 4 of the studies
Figure 1. Flow chart of selection of studies.
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at the initiation of the study.34-37 The total number of
participants in all studies analyzed was 182.
Of the 6 studies reviewed, 5 showed no significant
difference in volume of milk production, mean infant weight
gain, or time to relactation between the 2 study groups.34-38
The 2 studies that looked at ability to successfully establish
lactation or relactation found that the majority of mothers in
both the treatment and control groups were able to do
so.36,38 A single study with a small sample size33 found that
infants of mothers treated with metoclopramide consumed
significantly more milk than infants of mothers treated with a
placebo. Side effects were either not reported by au-
thors,34,36,37 not reported by participants,33,38 or, when
reported, were not significantly different between treatment
and control groups.35
Herbal Galactagogues
Table 3 summarizes the identified studies of common
herbal galactagogues.39-46 Eight blinded, placebo-con-
trolled trials of herbal galactagogues were identified; 2 for
Trigonella foenumgraecum (fenugreek),42,43 2 for Asparagus
racemosus (shatavari),40,41 1 for a micronized form of
silymarin45 (a standardized extract of Silybum marianum
[milk thistle]), 1 for Allium sativum (garlic),46 and 2 for
Moringa oleifera (malunggay).39,44 Results for torbangun
leaves in the Damarik et al study42 are not reported here
because the substance is not an outcome of interest in our
review. The total number of participants in all studies was
526 including the group given torbangun42 and 503
excluding this group. Although other herbs were identified
as commonly used to induce or augment lactation, such as
Cnicus benedictus (blessed thistle), Galega officinalis
(goat’s rue), and Foeniculum vulgare (fennel), no peer-
reviewed publications on these herbal preparations were
identified that met inclusion criteria.
Five of the studies were double-blind, randomized,
placebo-controlled trials,39-43 1 study was a single-blind,
randomized, placebo-controlled trial,44 1 study was double-
blind and placebo-controlled but not randomized,45 and 1
study was single-blind and placebo-controlled with ran-
domization not reported by the authors,46 although charac-
teristics of the treatment and control groups were not
statistically different at baseline in the latter 2 studies. Three
studies recruited women who were specifically identified as
experiencing inadequate lactation or borderline-normal milk
production,40,41,45 4 studies recruited mothers who deliv-
ered at term and began treatment soon after delivery,39,42-44
and 1 study recruited mothers who were exclusively breast-
feeding their infants.46 The herbal galactagogues were
either prepared as a tea or given as a capsule, and the form
of the placebo matched that of the treatment in each study.
No information was provided on methodology to mask the
taste and/or smell of the herbal galacatagogues (which may
result in unblinding of participants).
Milk production (mL or g) was estimated in 5 of the
studies, 3 of which used infant weight gain after feeding as a
proxy,42,45,46 while the other 2 measured the volume of milk
produced pumping each breast.43,44 Three studies mea-
sured serum prolactin and increase in infant weight.39-41
Of the 2 studies of shatavari root extract,40,41 only the
study by Gupta and Shaw41 reported a significant effect on
serum prolactin levels and infant weight gain. Both studies
provided the supplement for a similar amount of time;
however, in the study by Sharma et al,40 the shatavari root
extract was mixed with other herbs at a ratio of 15 g per 100
g of mixture, and participants consumed 2 teaspoons twice
daily for 4 weeks. Participants in the Gupta and Shaw study
reporting an effect consumed 60 mg/kg body weight of
unmixed shatavari root daily for 30 days.41 Both studies had
a similarly small sample size (32 and 30 in the treatment
groups, respectively). All participants in the study by
Sharma et al in which no effect was seen40 were reportedly
provided with lactation counseling, while Gupta and Shaw41
did not report lactation support. Human side effects were
not reported by either study; however, Gupta and Shaw
tested high doses in mice and saw evidence of mortality at a
dose of 5,000 mg/kg body weight.41
Figure 2. Mean breast milk production results in select randomized controlled trials of
domperidone and placebo.28-32
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Two studies were identified that explored the effects of
fenugreek on breast milk production, both of which
recruited mothers of neonates who delivered at term.42,43
The studies had similar sample sizes, but the methodology
differed significantly. Turkyilmaz et al43 provided the
fenugreek as an herbal tea (200 mL, 3 times daily) to group
1, an apple tea as a placebo to group 2, and no supplement
to group 3; participants in all 3 groups received support
from a lactation consultant. Breast milk was collected on the
third day after delivery via an electronic breast pump to
estimate volume (mL). Damanik et al42 employed a 3-armed
design including fenugreek seeds in capsule form (600 mg,
3 times daily) in 1 arm, torbangun leaves as a soup in
another arm (torbangun is not a galactagogue of interest for
this review, so the results of this arm are not discussed), and
a placebo in capsule form in another arm. Lactation support
was not reported. Milk consumed was estimated by
weighing the infants before and after feeding at 2-week
intervals. Turkyilmaz et al43 reported that mothers who
consumed the fenugreek tea produced significantly more
milk than mothers in the other 2 groups (P¼0.004), while
Damarik et al42 reported no difference in the amount of milk
consumed from mothers in the fenugreek capsule group vs
the placebo group.
The single study evaluating the efficacy of micronized
silymarin included mothers experiencing borderline-normal
milk production (approximately 700 mL/d) and assigned
them to a placebo or treatment group to receive 420 mg/d.45
Mothers taking silymarin produced significantly (P<0.01)
more milk than the mothers taking a placebo on day 30 of
treatment (64.43% increase from baseline vs 22.51%
increase, respectively) and on day 63 of treatment
(85.95% increase from baseline vs 32.09% increase,
respectively).
The single study evaluating the efficacy of garlic as a
galacatagogue recruited healthy mothers of exclusively
breast-feeding infants.46 Milk intake was estimated based
on the child’s weight gain after feeding in 3 groups: a
placebo group, a group receiving garlic on days 5-7, and a
group receiving garlic on days 8-11 of treatment. The
different timing of treatment with garlic was used to
investigate whether recent exposure had an impact on
infant milk intake. No significant difference was detected
between any of the groups at the study’s end (P>0.05).
Two studies investigated the use of capsules of malung-
gay leaves as a galacatagogue.39,44 The study by Espinosa-
Kuo was blinded only to the participant and utilized
capsules of 350 mg given twice daily for 8 days starting
the third day postpartum and measured milk output (mL)
from a manual pump.44 Yabes-Almirante and Lim provided
mothers with 250-mg capsules twice daily for 4 months
beginning within 6 hours of birth and measured serum
prolactin levels (mIU/L) at 3 timepoints: within 6 hours of
delivery before capsule administration and the first feeding,
at 48 hours after delivery 30 min after infant suckling, and at
4 months postpartum 30 min after suckling. Yabes-
Almirante and Lim also measured infant weight (kg)
immediately after birth, at 1 week, 2 weeks, 1 month, and
4 months of age.39 Espinosa-Kuo described greater milk
production in the group given malunggay capsules on each
day of treatment.44 At day 3 postpartum, mean breast milk
production was 96.4 – 14.3 mL among women in the
treatment group and 78.6 – 9.8 mL among women in the
control group. On day 10 postpartum, the mean volume of
milk production among women in the treatment group was
395.9 – 36.3 mL, while women in the control group
produced an average of 150.8 – 16.5 mL. No significant
difference between treatment and control groups was
detected on any day; however, exact P values were not
provided for any time point.
DISCUSSION
Pharmaceutical Galactagogues
The results of this review suggest that domperidone may
be efficacious in enhancing milk production in mothers
experiencing some degree of lactation failure,28-30,32 or with
less compelling evidence, in mothers who delivered via
cesarean section.31 Only 2 domperidone studies28-30
provided breast-feeding counseling to all participating
mothers before the start of the study. These studies28-30
were described as having low risk of bias in a metaanalysis
published in 2012.47 In the remaining 2 studies included in
this analysis, domperidone was administered within 2 days
postpartum without provision of lactation counseling to
resolve underlying issues.31,32
Systematic reviews of domperidone also indicate that the
dopamine antagonist has shown effectiveness in increasing
milk supply, although some controversy exists in the
literature on the efficacy and safety of domperidone as a
galactagogue.47,48 Domperidone has been extensively
studied in clinical trials for gastric motility49 and has
specifically been studied in infants as a treatment for
gastroesophageal reflux disease.50-53 Previous research
suggested that domperidone could increase the risk of
sudden cardiac death or could be linked with increased risk
of prolonged QT syndrome and arrhythmia;54 however,
sudden death resulting from prolongation of QT intervals
has never been reported with oral doses.49 A Health Canada
advisory notes that sudden cardiac death is only associated
with domperidone use in women >60 years and that these
risks likely do not apply to women of childbearing age
without heart conditions; therefore, extensive history should
be considered before administration of domperidone.55
Although domperidone has been available worldwide
since 1978, the US Food and Drug Administration (FDA) has
never approved its use for any indication. In 2004, the FDA
issued an alert, citing concerns over its use by breast-
feeding mothers and instituted a block of any personal
importation of domperidone.56 The alert cited cardiac side
effects from the intravenous formulation of domperidone
(without specific reference to published literature), although
the intravenous formulation was removed from the market in
the early 1990s and had been used almost exclusively for
patients receiving chemotherapy.57 Domperidone does not
appear to cross the blood-brain barrier as easily as
metoclopramide, and very little of the drug appears to
transfer into breast milk; a relative infant dose of approxi-
mately 0.012% at a 30-mg maternal intake daily and 0.009%
at 60 mg daily is estimated.58 Additionally, domperidone
does not appear to have adverse effects or cause tardive
dyskinesia—a condition involving repetitive and involuntary
body movements—when taken at such doses.9 Mild to
moderate side effects include dry mouth, headache, and
abdominal cramping, and one study suggests that these
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may be more prevalent as the dose of domperidone
increases, although milk production may not be significantly
greater at higher doses (60 vs 30 mg/d).58
Metoclopramide, another dopamine antagonist, is one of
the only prescription medications widely accepted to impact
milk supply and may also be prescribed off-label by health
providers in the United States. Despite its popularity as a
galactagogue, evidence from randomized, placebo-con-
trolled clinical trials appears insufficient. The current review
included clinical trials that collected baseline data and used
a placebo group. Of the 6 identified studies on metoclopra-
mide, 5 failed to show a significant difference in milk
production or time to relactation between treatment groups.
Little research on metoclopramide as a galactagogue is
available, despite the potentially serious and well-known
side effects and off-label prescribing.9,24,59-62 Depression
and tardive dyskinesia, along with cardiac arrest and severe
neuropsychiatric side effects, have been documented
following the use of metoclopramide, even in cases of
short-term exposure in otherwise healthy individuals.63-67
Mild to moderate side effects of metoclopramide are more
prevalent than those of domperidone in women using the
drugs to increase lactation. A study comparing domper-
idone with metoclopramide for breast milk production found
that 15 women reported side effects from metoclopramide,
whereas 3 reported side effects from domperidone.68
Additionally, metoclopramide is known to cross the blood-
brain barrier more easily and is secreted into breast milk at
higher levels than domperidone.69 The number of women
taking metoclopramide off-label to improve milk supply is
unknown, and it is imperative that further research be
conducted to establish therapeutic benefit and potential
risks.
The studies included in this review suggest that domper-
idone may be more effective in increasing breast milk
production than metoclopramide. While clinicians should
continue to provide exhaustive counseling before the use of
pharmaceutical galactagogues, many women experiencing
difficulties with lactation are at a great risk of not breast-
feeding and are mothers for whom other interventions have
proven to be least effective.70 More evidence from high-
quality studies is needed to determine effectiveness and
safety of domperidone as a galacatagogue to increase
confidence among clinicians when recommending a ga-
lactagogue if a mother wishes to induce lactation. Domper-
idone has been granted orphan drug status in the United
States, obtained by Dr Thomas Hale, and more data will be
available once approval for clinical trials is granted.10 A
randomized controlled trial of the use of domperidone for
increasing breast milk among mothers of preterm infants
was completed in March 2016 in Canada and is a rare
example of a pharmaceutical (or herbal therapy) being
rigorously studied for lactation.71 Results are pending.
Herbal Galactagogues
Evidence from the studies of herbal preparations to
increase lactation was mixed, as shown in Table 3. Only 3
of the popular herbs—shatavari, fenugreek, and malung-
gay—had more than 1 study identified for this review, and
the results were statistically significant in only 1 of the
studies for each herb. Additionally, inconsistencies in
methodology, participant recruitment, dosage, and out-
comes of interest make interpretation of evidence difficult.
Participants in the 2 studies on shatavari root extract had
similar characteristics: infants were born at term, and
mothers were experiencing some degree of lactation
failure.40,41 However, lactation counseling was only reported
in the study that failed to show a significant difference
between groups, and the shatavari root extract was given
with a combination of other herbs to the treatment group,
making it impossible to isolate the effect of the herb under
investigation.40 Information on lactation counseling was not
reported in the other study on shatavari root extract.41 More
evidence is needed to determine the utility of shatavari root
extract for lactation. Future studies must isolate the herb
under study and provide comparable access to lactation
counseling to attribute significant differences in milk
production to that herb. Based on rat models, shatavari
root may increase lactation via an estrogenic effect on the
mammary glands and increased prolactin production.72
While fatalities occurred in mice given long-term high doses
(5,000 mg/kg body weight) of shatavari root extract,41
potential side effects in humans at moderate doses have
not been documented.
Regarding fenugreek seed, a popular and widely avail-
able herb, mothers of healthy neonates treated with a
fenugreek tea 3 times daily produced significantly more
breast milk than mothers in the placebo group,43 while in
another study, mothers of full-term neonates who were
treated with 600-mg capsules of fenugreek seeds 3 times
daily for 1 month did not show a significant difference in milk
production compared with the placebo group.42 The
proposed mechanism for the augmentation of breast milk
through fenugreek supplementation is by its reported effect
on the stimulation of sweat production (the mammary gland
is a modified sweat gland).72 Many products available for
purchase commercially contain fenugreek (ie, More Milk
[Motherlove Herbal Company], fenugreek seeds [Nature’s
Way Products, LLC]); however, current evidence regarding
the efficacy of fenugreek in increasing milk production is
insufficient. Fenugreek was the herb most commonly used
by women surveyed in Australia: 56% reported its use,
98.2% of whom used it to increase breast milk supply.22 Of
lactation consultants surveyed, 15% in Switzerland and 99%
in Canada reported that they had used fenugreek to
increase lactation.27 Additionally, sales of fenugreek in-
creased 137.7% in the United States between 2012 and
2013.25 Adverse events were not reported in the studies
identified; however, fenugreek may cause side effects such
as nausea, vomiting, and decreased glucose levels in the
mother and diarrhea in the child.73
Healthy mothers who delivered infants at term were
recruited in the 2 studies that investigated the efficacy of
malunggay leaves; however, 1 study measured breast milk
production (mL) after pumping for a minimum of 5 min for
each breast,44 while the other measured serum prolactin
and infant weight gain.39 Although more milk was produced
by mothers receiving treatment than those receiving a
placebo (mean milk production was 395.9 – 36.3 mL in the
treatment group compared to 150.8 – 16.5 mL in the control
group on the last day of treatment), the former study failed
to show a significant difference between groups.44 In the
latter study, women in the treatment group had significantly
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higher levels of prolactin in the 48 hours after delivery than
women in the placebo group, and babies in the treatment
group weighed significantly more than those in the placebo
group at 4 months.39 These results merit more investigation,
as malunggay leaves are commonly used among breast-
feeding mothers in the Philippines to augment breast milk
production, and a pooled analysis of 6 studies on the
efficacy of Moringa oleifera (some of which were not
identified for this review because of inclusion criteria)
demonstrated a significant increase in milk produced 4-7
days after treatment.74 The change in serum prolactin levels
was measured in 1 of the studies of malunggay leaves, and
prolactin was significantly higher in the treatment group
compared to the placebo group.39 In a 2015 study by Stohs
and Hartman, no adverse events were reported in single
doses up to 50 g or when a dose of 8 g/d was sustained for
40 days in human models or at doses up to 2,000 mg/kg
body weight in rats.75
Of the studies identified, only one focused on silymarin. Di
Pierro et al examined the effect of micronized silymarin on
breast milk production in women experiencing borderline-
normal milk production (700 mL/d).45 Silymarin comprises
65%-80% of milk thistle extract.76 Women in the treatment
group produced 64.43% more milk than those in the placebo
group, suggesting potential efficacy, although more evidence
is needed to support this possibility.45 Milk thistle may cause
an allergic reaction and have a laxative effect.73
No significant difference was found between treatment and
placebo groups in a study on the efficacy of garlic in
increasing breast milk production in healthy mothers who
were exclusively breast-feeding their infants.46 A review of
herbs used by mothers who are breast-feeding identified garlic
as a galacatagogue and noted that the use of garlic may deter
an infant from suckling if he or she finds the odor offensive.73
A 2012 review of pharmaceutical and herbal galacta-
gogues surveyed the evidence for the pharmaceutical use
of domperidone, metoclopramide, and oxytocin along with
the efficacy of herbal galactagogues, including fenugreek,
milk thistle, and shatavari.59 The review reached a similar
conclusion to the current one, that domperidone may be
efficacious after nonpharmacologic methods are exhausted,
although safety information is limited and requires further
investigation. The authors of that review did not draw any
conclusions about the efficacy of herbal galactagogues
because of limited evidence.
The most extensive compilation of evidence on herbals,
including their use as galactagogues, is The Complete
German Commission E Monographs: Therapeutic Guide to
Herbal Medicines; however, it is beyond the scope of our
review.77
Popular Demand for Galactagogues
Herbal galactagogues are now widely available over the
counter in the United States and other countries, and
information is commonly sought on galactagogues and
other means to increase or initiate lactation. Figure 3
presents an analysis of the relative popularity (number of
searches at that time point divided by largest number of
searches for that particular term in the time period) of
Google searches for the term increase breast milk between
January 1, 2004, and August 18, 2015, suggesting that the
demand for information on galactagogues has been
steadily increasing during the past decade. An internet
search revealed >1.16 million distinct website references to
breast-feeding and herbs and >100 herbal product descrip-
tions containing the term lactation, breast milk, or milk for
sale online to increase milk production (authors’ search
conducted August 11, 2015). The authors’ search of the
term increase breast milk at www.amazon.com on August
11, 2015, revealed that popular products (those with at least
a 4-star rating and >100 reviews) frequently contained
fenugreek, milk thistle, and goat’s rue. Only herbs that have
been studied in a scientific trial are included in this review.
Exploratory work in Australia found that the majority of
participants who reported using herbs for medicinal purpos-
es during breast-feeding—approximately half of whom were
using these supplements to augment breast milk produc-
tion—believed there was a lack of informational resources
regarding their use, and only 28.6% notified their doctors that
they were using herbal supplements.22 Nearly three-quarters
(71.6%) reported avoiding conventional medicines to ad-
dress breast-feeding, citing concerns regarding safety to
their breast-fed infants, and many expressed the desire for
more evidence-based information from healthcare profes-
sionals regarding the use of herbal medications during
breast-feeding.22,26 Demand for herbal galactagogues ap-
pears to be high; however, herbal products, including teas,
tinctures, and capsules may not be regulated by government
bodies and are not required to be tested in humans prior to
sale. In the United States, the FDA does not analyze the
content of dietary herbal supplements before they are
marketed. While the manufacturer is prohibited from making
false or misleading claims on the packaging, a disclaimer is
often used to clear culpability, and action is not taken until
after the product reaches market.78 Various herbal medicines
that have very low amounts of active ingredients, as well as
those that have resulted in adverse effects, have emerged
during the past decade.79
Despite the dearth of evidence supporting the safety and
effectiveness of herbal galactagogues, 69% of surveyed
certified US lactation consultants reported that they had
heard of herbal remedies for lactation, and 65% of those
said that they recommended one or more of these methods
to mothers.80 Adverse effects of herbal galactagogues are
not well understood in human subjects; however, high
dosages of some herbal galactagogues are often purport-
edly required to stimulate milk production. One of the most
commonly used herbs, fenugreek, may be potentially taken
in high doses, as women are often advised to use doses to
‘‘smell like maple syrup.’’81 More high-quality evidence is
needed to support the recommendation of herbal galacta-
gogues by clinicians and lactation consultants. No pub-
lished reports were identified of protocols for trials
underway to assess the impact of common herbal galacta-
gogues on lactation or breast-feeding.
STRENGTHS AND LIMITATIONS
Strengths of our review include a comprehensive search
strategy with the use of multiple databases, well-defined
inclusion and exclusion criteria to identify high-quality
studies, and the addition of the Google Trends analysis to
provide insight on consumer demand related to the use of
galactagogues. Limitations of the study include review of
only English language articles, which may have excluded
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relevant studies in other languages, and use of only large
biomedical databases, which may have excluded studies
not abstracted in those databases but pertinent to the topic.
Additionally, a complete and thorough analysis of the
quality of the studies included was beyond the scope of
this review. We were also unable to provide an exhaustive
review of herbs commonly used, but not commercially
available, which may have been studied in other databases
than those we searched.
CONCLUSION
Regarding pharmaceutical galactagogues, not enough
information is available for clinicians and patients to make
informed decisions on their use. Clinicians face complex
decisions in counseling women experiencing difficulties with
lactation or those who want to induce lactation. Considering
the apparent demand for galactagogues and the low rates of
sustained breast-feeding worldwide, this lack of reliable
information is an important issue because clinicians and
families may not be able to make safe choices when
confronted with difficulties related to lactation. More informa-
tion from well-controlled trials is needed to guide appropriate
use of pharmaceutical and herbal galactagogues.
Regarding herbal galactagogues, the evidence is also
inadequate to guide clinical recommendations. Future studies
must employ robust study designs, recruit participants
experiencing lactation failure, and provide lactation counsel-
ing to all participants. Evidence from future studies should
also be used to inform policies on safety that can be enforced
by government bodies, particularly for herbal supplements,
as well as clear and informative standardized labeling to guide
women in using supplements during lactation.
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